CellSource Co., Ltd. (4880.T)
JPY 663.0
(1.84%)
JPY 663.0
(1.84%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.3 Billion JPY | -23.05% |
| 2022 | 1.64 Billion JPY | 57.45% |
| 2021 | 1.06 Billion JPY | 137.33% |
| 2020 | 476.45 Million JPY | 35.55% |
| 2019 | 365.44 Million JPY | 5.09% |
| 2018 | 309.64 Million JPY | 81.5% |
| 2017 | 169.92 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 106 Million JPY | 7.98% |
| 2024 Q1 | 231.51 Million JPY | 32.3% |
| 2024 Q3 | 134.67 Million JPY | -44.17% |
| 2023 Q3 | 388.96 Million JPY | 22.31% |
| 2023 FY | - JPY | -23.05% |
| 2023 Q4 | 158.24 Million JPY | -59.32% |
| 2023 Q2 | 318.01 Million JPY | -4.87% |
| 2023 Q1 | 334.31 Million JPY | -48.42% |
| 2022 Q4 | 648.19 Million JPY | 43.82% |
| 2022 FY | - JPY | 57.45% |
| 2022 Q2 | 251.02 Million JPY | 2.48% |
| 2022 Q1 | 244.94 Million JPY | -22.66% |
| 2022 Q3 | 450.68 Million JPY | 79.54% |
| 2021 Q2 | 254.69 Million JPY | 40.83% |
| 2021 Q1 | 180.86 Million JPY | 11.06% |
| 2021 Q3 | 256.24 Million JPY | 0.61% |
| 2021 Q4 | 316.71 Million JPY | 23.6% |
| 2021 FY | - JPY | 137.33% |
| 2020 Q4 | 162.84 Million JPY | 158.48% |
| 2020 Q2 | 63.72 Million JPY | -48.41% |
| 2020 Q1 | 123.52 Million JPY | 53.58% |
| 2020 FY | - JPY | 35.55% |
| 2020 Q3 | 63 Million JPY | -1.13% |
| 2019 FY | - JPY | 5.09% |
| 2019 Q4 | 80.42 Million JPY | 0.0% |
| 2018 FY | - JPY | 81.5% |
| 2017 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | -36.357% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | 367.641% |
| GNI Group Ltd. | 14.48 Billion JPY | 90.983% |
| Linical Co., Ltd. | 1.24 Billion JPY | -4.747% |
| Trans Genic Inc. | 240.95 Million JPY | -442.199% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 196.355% |
| Soiken Holdings Inc. | -583.2 Million JPY | 324.01% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | 316.624% |
| AnGes, Inc. | -8.86 Billion JPY | 114.745% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 201.629% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 117.657% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | -919.804% |
| NanoCarrier Co., Ltd. | -863 Million JPY | 251.384% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 219.661% |
| CanBas Co., Ltd. | 53.65 Million JPY | -2335.071% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | 268.444% |
| RaQualia Pharma Inc. | -111.8 Million JPY | 1268.541% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 207.815% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 194.613% |
| PeptiDream Inc. | 7.37 Billion JPY | 82.288% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 167.702% |
| Ribomic Inc. | -1.01 Billion JPY | 229.028% |
| SanBio Company Limited | -4.52 Billion JPY | 128.872% |
| Healios K.K. | -3 Billion JPY | 143.447% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 212.065% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 193.781% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 193.184% |
| StemRIM | -2.03 Billion JPY | 164.293% |
| FunPep Company Limited | -952 Million JPY | 237.231% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 246.995% |
| Stella Pharma Corporation | -723.85 Million JPY | 280.484% |
| TMS Co., Ltd. | -937 Million JPY | 239.428% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 268.488% |
| Cuorips Inc. | -518 Million JPY | 352.208% |
| K Pharma,Inc. | 366.05 Million JPY | -256.894% |
| Takara Bio Inc. | 8.02 Billion JPY | 83.718% |
| ReproCELL Incorporated | 8.24 Million JPY | -15745.24% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | -1385.638% |
| StemCell Institute Inc. | 534.35 Million JPY | -144.49% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | -433.646% |
| CellSeed Inc. | -836.51 Million JPY | 256.176% |